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ABSTRACT

Polyamine compounds, method of synthesis and method of
use for anti-cancer purposes, for enhancing the activity of
existing anti-cancer drugs, as well as, for inhibiting N-Methy1-D-Aspartate (NMDA) receptors found in neurotransmission systems are provided. Certain polyamine motifs have
been identified that can be attached to toxic agents to facilitate
their access to cancer cells as well as polyamine compounds
of surprising cytotoxicity with selectivity in killing cancer
cells, and surprising utility in the treatment of Alzheimer's
disease and brain stroke. It includes an illustrative conjugate
system with examples of a triamine or a tetraamine appended
to a cytotoxic agent. Included is a general strategy to enhance
cell uptake by attaching a polyamine vectoring system with
an example of a triamine vector attached to an existing anticancer drug to improve its chemotherapeutic potency. There
is an illustration of tetraamine derivatives which have surprising enhanced selectivity in inhibiting N-methyl-D-aspartate
(NMDA) receptors involved in neurotransmission. Several
ligands can affect the activity of this receptor, which has been
shown to initiate cell death under stroke conditions (lack of
oxygen). Tetraamine derivatives which bind or inhibit the
action of the NMDA receptor provide new therapy for
NMDA-associated human diseases, such as Alzheimer's disease and stroke.
4 Claims, 13 Drawing Sheets
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Figure 2B
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Figure2C
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Figure 6A.
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Figure6B.
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POLYAMINE CONJUGATES AS SELECTIVE
NMDA INHIBITORS AND ANTI-CANCER
DRUGS

N-piperidinyl, and pyridinyl units. Bowlin referred to above
should be considered with respect to Colunm 1, lines 51-67 in
which is described compounds useful for potentiating the
cellular immune response. Bowlin's compounds are limited
to activating cells to be killed by the immune system. Thus,
Bowlin requires an immune system to work with their disclosed drugs.
Other research in using polyamine conjugates for cellular
entry has been described in published documents (Cohen, G.
M.; Cullis, P.; Hartley, J. A.; Mather, A. Symons, M. C. R.;
Wheelhouse, R. T. Targeting of Cytotoxic Agents by
Polyamines: Synthesis of a Chloroambucil-Spermidine Conjugate. J. Chem. Soc. Chem. Commun. 1992, 298-300; Cullis,
P. M.; Merson-Davies, L.; Weaver, R. Conjugation of a
polyamine to the bifunctional alkylating agent chlorambucil
does not alter the preferred cross-linking site in duplex DNA.
J. Am. Chem. Soc. 1995, 117, 8033-8034; Phanstiel IV, O.;
Price, H. L; Wang, L.; Juusola, J.; Kline, M.; Shah, S. M. The
Effect of Polyamine Homologation on the Transport and
Cytotoxicity Properties of Polyamine-(DNA-Intercalator)
Conjugates. J. Org. Chem. 2000, 65, 5590-5599; Wang, L.;
Price, H. L.; Juusola, J.; Kline, M.; Phanstiel, IV, 0. "Influence of Polyamine Architecture on the Transport and Topoisomerase II Inhibitory Properties of Polyamine DNA-Intercalator Conjugates," J. Med. Chem. 2001, 44, 3682-3691;
Delcros, J-G.; Tomasi, S.; Carrington, S.; Martin, B.; Renault,
J.; Blagbrough, I. S.; Uriac, P. Effect ofspermine conjugation
on the cytotoxicity and cellular transport of acridine. J. Med.
Chem., 2002, 45, 5098-5111; "Synthesis and Biological
Evaluation of N 1 -(anthracen-9-ylmethyl)triamines as
Molecular Recognition Elements for the Polyamine Transporter," Wang, C.; Delcros, J-G.; Biggerstaff, J.; Phanstiel IV,
0. J. Med. Chem., 2003, 46, 2663-2671; "Molecular Requirements for Targeting the Polyamine Transport System: Synthesis and Biological Evaluation of Polyamine-Anthracene
Conjugates," Wang, C.; Delcros, J-G.; Biggerstaff, J.; Phanstiel IV, 0. J. Med. Chem. 2003, 46, 3672-2682; "Definingthe
Molecular Requirements for the Selective Delivery of
Polyamine-Conjugates into Cells Containing Active
Polyamine Transporters," Wang, C.; Delcros, J-G.; Cannon,
L.; Konate, F.; Carias, H.; Biggerstaff, J.; Gardner, R. A.;
Phanstiel IV, 0. J. Med. Chem. 2003, 46, 5129-5138; "N 1 Substituent Effects in the Selective Delivery of PolyamineConjugates into Cells Containing Active Polyamine Transporters"Gardner, R. A.; Delcros, J-G.; Koriate, F.; Breitbeil
III, F.; Martin, B.; Sigman, M.; Huang, M.; Phanstiel IV, 0. J.
Med. Chem. 2004, 47, 6055-6069.)

This is a Divisional ofapplication Ser. No. 10/994,108 filed
Nov. 19, 2004 now abandoned which is a Continuation-InPart of application Ser. No. 10/667,288 filed Sep. 19, 2003,
now U.S. Pat. No. 7,001,925 issued on Feb. 21, 2006, which
claims the benefit of priority to U.S. Provisional Patent Application No. 60/414,037 filed Sep. 27, 2002.
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FIELD OF INVENTION
This invention relates to polyamine compounds and more
particularly to tetraamine derivatives and their use as N-Methyl-D-Aspartate (NMDA) inhibitors for therapeutic treatment of neurodegenerative disorders, such as stroke, Alzheimer's disease, other neurodegenerative disorders, their use
as anticancer agents and their use as a vector for the enhancement of anti-cancer drug activity.

15

20

BACKGROUND AND PRIOR ART
Neurodegenerative disorders and cancer are major causes
ofillness and death in the western world. Healing treatment or
therapy for neurodegenerative disorders, such as brain stroke,
Alzheimer's disease, and Parkinson's disease have eluded the
medical and pharmaceutical industries for decades. A key
finding is that oxygen-deprived nerve cells produce high levels of glutamate, which stimulate a receptor called an N-Methyl-D-Aspartate (NMDA), known for its ability to cause
neuron cell death. Thus, the ability to control the activity of
NMDA receptors has become the focus of neuroscience
research.
With regard to cancer therapies, one of the major shortcomings of current cancer therapies is the non-selective delivery of the antineoplastic drug to both targeted tumor cells and
healthy cells. Enhanced selectivity of such drugs could
diminish their associated toxicity by reducing their uptake by
healthy cells. Moreover, selective delivery would increase
drug potency by lowering the effective dosage required to kill
the affected cell type. Vectored systems, which have
enhanced affinity for cancer cells would be an important
advance in cancer therapy.
Polyamines are naturally occurring amines, which form
polycations in vivo. These stabilize DNA architectures and
are cellular growth factors. All cells contain some form of the
native polyamines: putrescine, spermidine or spermine. Rapidly dividing cells (such as cancer cells) require large
amounts of polyamines, and cells can either biosynthesize or
import these essential growth factors. Many tumor cell lines
have been shown to have very high levels of polyamines and
an active polyamine transporter.
Polyamine structures have been exploited for use in various drug strategies, such as demonstrated in U.S. Pat. Nos.
Bergeron, 6,342,534 and 5,866,613; Prakash, 5,109,024;
Iwata 6,319,956 and Published application 2002/0067472
Al; Bowlin 5,719,193; and, Klose! 6,281,371 Bl and published document "A Comparison of Structure-Activity Relationships between Spermidine and Spermine Analogue Antineoplastics," by Bergeron, R. J.; Feng, Y.; Weimar, W. R.;
McManis, J. S.; Dimova, H.; Porter, C.; Raisler, B.; Phanstiel
IV, 0. J. Med. Chem. 1997, 40, No. 10, 1475-1494.
Bergeron U.S. Pat. No. 6,342,534 should be considered
with respect to Column 3, lines 51-67 and Column 4, lines
39-48, Table 1 and Table 2, in which the emphasis is on
bis-substituted tetraamine systems terminated with N-ethyl,

25
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The prior art by Cullis et al is limited to delivering a DNAalkylating agent (chlorambucil) to cells using spermidine, a
non-optimal polyamine vector. The chlorambucil substituent
is linked via a tether to the internal N4 -nitrogen of the spermidine chain. Recent findings have shown this internal
N-alkylation motif used by Cullis to be a less than optimal
arrangement for using the polyamine transporter. The previous publications by Phanstiel IV et al are limited to branched
polyamine systems built from spermine and spermidine platforms, again using non-optimized polyamine vectors. The
report by Blagbrough et al focused on using tetraamine
derivatives of spermine to deliver acridine to cells. Blagbrough's compounds are limited by the use ofless than optimal spermine vectors to deliver a less potent acridine drug
into cells.
The more recent Phanstiel IV papers (2003-2004) illustrate
this technology with linear triamines and tetraamine systems
in targeting cancer cells via the polyamine transporter.
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Since the 1980s several laboratories have probed the transsatisfy a very significant commercial demand in the medical
and pharmaceutical industries.
port properties of polyamines into various cell types (E. coli,
yeast and mammals). The polyamine transporter inE. coli is
SUMMARY OF THE INVENTION
perhaps the best understood as the transporter gene and several protein gene products (PotA-F) have been identified. In
The first objective of the present invention is to provide
particular the PotB and PotC proteins form a trans-membrane
compounds that are useful as anti-cancer agents and useful as
channel, which facilitates polyamine transport. PotD is a
therapeutic treatments for neurodegenerative disorders.
periplasmic, polyamine-binding protein, which prefers sperThe second objective of the present invention is to provide
midine overputrescine. Moreover, the X-ray crystal structure 10
a method for enhancing the efficacy of anti-cancer agents and
of spermidine bound to PotD revealed that the molecular
N-Methy1-D-Aspartate (NMDA) receptor inhibitors.
recognition events involved in spermidine binding is conThe third objective of the present invention is to provide a
trolled by specific amino acid residues and a bound water
method for preparing the anti-cancer compounds and commolecule. Specifically, through this water molecule, the
pounds having surprising utility as NDMA inhibitors for
bound spermidine molecule forms two hydrogen bonds with 15 treatment of neurodegenerative disorders.
Thr 35 and Ser 211. In a related study the PotF protein was
The fourth objective of the present invention is to provide
shown to selectively bind putrescine. The PotF crystal struccompounds and methods for treating cancer cells without
ture, in combination with the mutational analysis, revealed
requiring the immune system.
the residues crucial for putrescine binding (Trp-37, Ser-85,
The fifth objective of the present invention is to provide a
Glu-185, Trp-244, Asp-247, and Asp-278) and the impor- 20 very selective N-Methyl-D-Aspartate (NMDA) inhibitor that
tance of water molecules for putrescine recognition. Thereprotects nerve cells from dying and could be used as a therapy
fore, the E. coli studies provided a striking example of how
for victims of stroke and other neurodegenerative diseases.
cells can discriminate between structurally similar di- and
Preferred embodiments of this invention include:
tri-amine substrates, (e.g., putrescine (PUT) and spermidine 25
Compounds of the formula A,
(SPD), respectively). While significant work has also been
accomplished in yeast and other systems, the proteins
A
involved in mammalian polyamine transport have not yet
been isolated and characterized beyond a kinetic description.
or a pharmaceutically acceptable salt thereof, wherein R is
Clearly, the lack of structural detail associated with the mam- 30 selected from the group consisting of naphthylmethyl, naphmalian polyamine transporter is a glaring void in the knowlthylethyl, anthracenylmethyl, anthracenylethyl, pyrenylmedge base.
ethyl, R1, R2 , R 3 , and R4 are selected from at least one of
hydrogen,
alkyl, cycloalkyl, alkylaryl, para-toluenesulfonyl,
The NMDA receptor is known to have a polyamine binding
arenesulfonyl, alkylsulfonyl, acyl, carbamoyl, and r is 2-18
site, which modulates its action. Moreover, it is known that
the site(s) responsible for both the agonist and antagonist 35 ands is 2-18;
activity of polyamine derivatives reside in a single subunit of
Compounds of the formula B,
the NMDA receptor-channel complex (NR2). This phenomB
enon has been reported in Ransom, R. W.; Stec, N. L.; Cooperative Modulation of[3H]MK-801 binding to then-methyl40 or a pharmaceutically acceptable salt thereof, wherein R is
D-Aspartate Receptor ion Channel by Glutamate, Glycine
selected from the group consisting of naphthylmethyl, naphand Polyamines. J. Neurochem. 1988, 51, 830-836 and in
thylethyl, anthracenylmethyl, anthracenylethyl, pyrenylmWilliams, K.; Romano, C.; Molinoff, P. B. Effects of
ethyl, wherein R1, R 2 , R 3 , R4 andR5 are selected from at least
Polyamines on the binding of[3H] MK-801 to the N-methylone of the following: hydrogen, alkyl, cycloalkyl, alkylaryl,
D-Aspartate receptor: Pharmacological Evidence for the 45 para-toluenesulfonyl, arenesulfonyl, alkylsulfonyl, acyl, carExistence of a Polyamine Recognition Site. Mal. Pharmacol.
bamoyl and r is 2-18, sis 2-18 and tis 2-18;
1989, 36, 575-581 and Williams, K.; Zappia, A. M.; Pritchett,
Compounds of the formula C,
D. B.; Shen, Y. M.; Molinoff, P. B. Sensitivity of the N-Methyl-D-Aspartate receptor to polyamines is Controlled by
c
NR2 Subunits. Mal. Pharmacol. 1994, 45, 803-809. In 1995, 50
or a pharmaceutically acceptable salt thereof, where R is a
Bergeron et al. discussed multiple uses of polyamines in the
chemotherapeutic agent and R 1 -R4 are at least one of hydroJournal ofMedicinal Chemistry 1995, 38, 425-442, "Impact
gen, alkyl, acyl, carbamoyl or alkylaryl, and r is 2-18, ands is
of Polyamine Analogues on the NMDA Receptor." In addi2-18;
tion to antineoplastic activity against tumor cells, N-terminally dialkylated tetraamines were reported to have a potent 55 A compound of the formula D,
effect on neuromuscular activity in the gut, function in moduD
lating neural transmission and exhibit a pronounced biphasic
action on NMDA receptor function. What was not known is
or a pharmaceutically acceptable salt thereof, where R is a
the optimal polyamine architecture to selectively inhibit the
1
5
60 chemotherapeutic agent and R -R are at least one of hydroNR2 subunit of the NMDA receptor, a site responsible for
gen, alkyl, acyl, carbamoyl or alkylaryl, andris 2-18, sis 2-18
neuronal cell death. A success in this area would provide the
and tis 2-18; their use in pharmaceutical compositions; and
medical community with a new tool and potential therapy for
their methods of fabrication.
the treatment of stroke and neurodegenerative diseases.
The compounds of formulas B and D above are tetraamine
Indeed, very selective and effective tetraamine derivatives 65 derivatives and are preferred for use as NMDA inhibitors,
for treatment of neurodegenerative disorders, such as stroke,
while retaining their modest anti-cancer activity and will be
Alzheimer's disease, Parkinson's disease and the like would
explained in more detail below.
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Further objects and advantages of this invention will be
apparent from the following detailed descriptions of the presently preferred embodiments, which are illustrated schematically in the accompanying drawings.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 is a sample conjugate system with two examples,
triamine 8 and tetraamine 13.
FIGS. 2A, 2B and 2C (Schemes 1-4) provide general 10
method schemes for the synthesis of the compounds of the
invention.
FIG. 3 is a general strategy to enhance cell uptake by
polyamine vectoring systems.
FIG. 4 provides examples of an existing anti-cancer drug 15
doxorubicin substituted with either a triamine, e.g., 14 (or a
tetraamine, e.g., 15) to improve its chemotherapeutic
potency.
FIG. 5 (Scheme 5)-illustrates a synthetic method to attach
the polyamine vector onto an existing chemotherapeutic, 20
doxorubicin. This methodology can lead to the synthesis of
the polyamine-doxorubicin conjugate 14.
FIGS. 6A-6B (Schemes 6 and 7)-illustrates the synthesis
of various aryl substituted polyamines (27a, 27b, Se, 27d), a
hydroxylated polyamine derivative 30 and a cyclohexyl- 25
diamine analogue 31.
FIG. 7 illustrates the structures of 32-35 as examples of
systems with altered amine scaffolds appended to an anthracenyl methyl unit.
30
FIG. 8 illustrates a naphthylethyl triamine derivative, 36.
FIG. 9 illustrates an anthracenylethyl triamine derivative,
37.
FIG.10 shows the effect ofanthracene-spermine conjugate
on glutamate receptors.
35
FIG. 11 shows the effect of the anthracene control compound (without an attached polyamine) on the NMDA
(NR1A/NR2A) receptor.
DESCRIPTION OF THE PREFERRED
EMBODIMENTS
Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
particular arrangements shown, since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation. It would
be useful to discuss the definitions of some words used herein
and their applications before discussing the invention, which
provides compounds and methods for treating cancer cells
without requiring the immune system for their cytotoxicity
and for selectively inhibiting the activity of the NMDA receptor, a site present in neurotransmission systems that is responsible for neuron cell death. For the purposes of this patent
application, the term "vector" is used to denote a special
chemical message, which is recognized by the polyamine
transport system of cells. This special chemical message is a
polyamine with the proper or ideal spacing units in between
the nitrogen centers. Research has shown that having the
proper spacing unit (distance between the nitrogen centers)
and having the appropriate number of positive charges (via
protonation of the nitrogen centers) is critical for selective
cellular uptake.
1) "Vectored systems" relates to polyamine conjugates,
which have a polyamine message which is recognized
by the polyamine transport system on the surface of cells
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and have enhanced uptake into cells with highly active
polyamine transporters over those which do not, (e.g.,
CHO vs. CHO-MG cells).
2) The term "transporter" is used to describe the cellular
process of binding and/or importing a chemical entity,
which is outside the cell. The chemical entity in this case
is the polyamine conjugate, i.e. a polyamine scaffold
covalently attached to a toxic agent.
3) The term "conjugate" is used to describe a polyamine
architecture, which is covalently bound to a cytotoxic
agent (e.g., an anthracenyl methyl unit) or to a known
chemical agent with anti-cancer properties, e.g., doxorubicin.
4) "Cell selectivity" denotes the ability of a polyamine
conjugate to selectively enter cells with highly active
polyamine transporters (e.g. CHO cells or B16 melanoma cells) over those that have lower polyamine transport activity (e.g. CHO-MG cells or Mel-A cells).
5) "IC50 value" is the concentration of drug needed to kill
50% of the relative cell population. The lower the value
the more cytotoxic the drug is to that cell type. In Figures
before FIG. 10, the lower the IC 50 value, the higher
potency of the polyamine derivative in killing the cancer
cell type. In terms of FIGS. 10and11 which pertain to
NMDA activity, the lower the IC 50 value the more effective the polyamine derivative is in inhibiting the activity
of the particular receptor function. In this case, selective
inhibition of the NMDA receptor subunit NR1A/NR2A
provides cell protection.
6) "K, value" reflects the affinity of the drug architecture for
the polyamine transporter. The lower the value of the Ki,
the higher the affinity of the drug for the polyamine
transporter.
7) L1210 cells are mouse leukemia cells and are a standard
well-used benchmark for evaluating cytotoxicity of new
drug systems, especially polyamine containing drugs.
8) Chinese hamster ovary cells (CHO cells) have an active
polyamine transporter. This cell type is very susceptible
to drugs, which use the polyamine transporter to gain
access to cells (i.e. polyamine conjugates).
9) Chinese hamster ovary cells, which are chemically
mutated to be polyamine transport-deficient will be
referred to as the CHO-MG cell line. This cell type
should have lower susceptibility to polyamine conjugates, which use the polyamine transporter to gain
access to cells, since it does not have an active transporter to facilitate their uptake.
10) B16 cells are melanoma, skin cancer cells with highly
active polyamine transporters. These cells should be
very susceptible to polyamine conjugates which use the
polyamine transporter to gain access to cells.
11) Mel-A cells are normal melanocytes, skin cells, which
have moderately active polyamine transporters. These
cells should be moderately susceptible to polyamineconjugates, but less so than the B-16 cells.
12) "NMDAreceptor" is the N-Methyl-D-Aspartate receptor, a brain protein in neurotransmission systems that is
crucial for learning and memory. When oxygen-deprived nerve cells occur, as in brain stroke, excess levels
of glutamate are produced, which stimulate the NDMA
receptor to cause nerve cell death with devastating
results. In particular, certain subunits of the NMDA protein complex are considered "bad" receptors as they
stimulate cell death (e.g. NR1A/NR2A). Other receptors
are considered' good" receptors which are necessary for
proper cell function (e.g., AMPA and GluRl ). The goal
is to selectively inhibit the bad receptor (NR1A/NR2A
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as evidenced by a low IC 50 value), while leaving the
good receptors operational (evidenced by a higher relative IC50 value in AMPA or GluRl ). This desired selectivity is illustrated in FIG. 10.
A recent discussion of the use of polyamine conjugates in
relation to N-Methyl-D-Aspartate (NDMA) receptors is by
Keiko Kashiwagi et al. in The Journal ofPharmacology and
Experimental Therapeutics 2004, Vol. 309, No. 3, SS4-S93,
"Anthraquinone Polyamines: Novel Channel Blockers to
Study N-Methyl-D-Aspartate Receptors."
This invention has identified polyamine compounds,
which have multiple functions, including, but not limited to,
surprising cytotoxicity, unexpected selectivity in killing cancer cells (or cells with active polyamine transporters), selectivity and potency for inhibiting the activity of the NMDA
receptors that trigger damage caused by oxygen deprivation
in the brain and/or facilitate the delivery of known toxic
agents into cancer cells.
A panel of amine substrates of the general formula indicated in FIG. 1 (i.e., those of general type Sand 13 as well as
other systems to be discussed later) were tested for efficacy in
cells containing active and deficient polyamine transporters
(i.e., Chinese hamster ovary CHO cells and CHO-MG cells,
respectively). In addition, murine leukemia (Ll 210) cells and
L1210 cells pretreated with DFMO (Difluoromethylornithine, an inhibitor of ornithine decarboxylase) were also
treated with the polyamines illustrated in FIG. 1 (i.e. those of
general type Sand 13) as well as other systems to be discussed
later. The results indicate micromolar concentration IC 50 values in three cell lines along with varying K, values (a transporter affinity measure) and are provided in Tables 1 and 2.
Table 1 illustrates the fact that different polyamine compounds have different cytotoxicity profiles, e.g., the IC 50
value varies from 0.3 to 36.3 uM in the L1210 cell study
(Table 1, colunm 2). The presence of di-fluoromethylornithine (DFMO) is known to enhance polyamine uptake into
L1210 cells and should make the cells more sensitive to the
tested polyamine analogues. Indeed, the IC 50 values were
typically lower in the presence ofDFMO (Table 1, colunm 3).
This finding is consistent with certain analogues using the
polyamine transporter to gain access to these cells. The distance separating the nitrogen centers was directly related to
cytotoxicity. Attaching the anthracenylmethyl subunit to a
particular polyamine "vector" motif provided enhanced cytotoxicity. The structures of compounds Sb-Sg are defined in
FIG. 2, Scheme 2. Note: the term "3,3-triamine" refers to the
fact that molecule Sb has two three carbon spacer units separating the three nitrogen centers.
For example in Table 1, Sb, a conjugate bearing the "3,3triamine" motif was only 1.3 fold more toxic in the presence
of DFMO, whereas the related 4,4-triamine motif Se was
twice as toxic. This effect was even more dramatic with
tetraamine systems 13e and 13f, which were 7.2 and 4.7 fold
more toxic, respectively, in the presence ofDFMO. The dramatic effect of tetraamine systems 13e and 13f contributed to
further study of the tetraamine conjugate systems in general,
including their use as a therapeutic treatment for neurodegenerative disorders. Note the control compounds 34 and 35,
which do not contain the properpolyamine vector, gave lower
cytotoxicity in the presence ofDFMO (both were 0.7 fold less
toxic). These results suggested that the observed cytotoxicity
enhancement with DFMO is related to the ability of the conjugate to utilize the polyamine transport system.
As shown in Table 2, these same controls 34 and 35 were
not very selective in killing CHO and CHO-MG cells as they
had similar toxicities in both lines. Indeed, specific structures
of the polyamine component were needed for the desired cell

selectivity. The triamines of the invention have demonstrated
over 150-fold higher cytotoxicity in killing cells with active
polyamine-transporters (as modeled by the CHO line) over
cells, which are polyamine-transporter deficient (as modeled
by the CHO-MG cell line). For example, the 4,4-triamine
conjugate Se was one of the most selective compounds and
was very toxic to CHO cells (IC 50 =0.45 µM), but much less so
to the CHO-MG cell line (IC 50 =66.7 µM).
While a few investigators have successfully "ferried"
polyamine-drug conjugates into cells, limited systematic
studies have been conducted on the mono-substituted linear
polyamines as vector systems. This, in part, may stem from
their less direct syntheses, which involve several steps. The
method of synthesis of some of the triamines (and tetraamines) of the invention are provided in examples below
and in FIGS. 2A, 2B, 2C, 5 and 6 (Schemes 1-7).
The initial conjugates are comprised of an anthracene
nucleus covalently bound to a polyamine framework. The
anthracene component was selected due to significant preliminary data, which revealed its increased potency over an
acridine analogue in murine leukemia (L1210) cells. Moreover, the anthracene provides a convenient UV "probe" for
compound isolation (and identification) and elicits a toxic
response from cells upon entry (presumably through DNA
coordination). The uptake of several anthracene-polyamine
conjugates by the polyamine transporter (PAT) has been demonstrated. The large size and sweep volume of the appended
anthracene system suggests that other architectures (e.g.,
doxorubicin) may also be conveyed into cells via this transporter. In fact, compound 27d, a pyrene derivative, is also
selectively imported into cells with active polyamine transporters. Therefore, while the anthracene component offers a
convenient probe for polyamine delivery studies, the invention is not limited thereto.
To optimize delivery, polyamine architectures are needed,
which facilitate uptake via the polyamine transporter (PAT).
The polyamine tail has been shown to facilitate uptake, impart
water solubility to the conjugate, and enable dosing as aqueous solutions.
Virtually all cells contain substantial amounts of at least
one of the polyamines: putrescine (PUT), spermidine (SPD),
or spermine (SPM). Since the polyamine component represents an important cellular "feedstock", one would expect
preferential uptake by rapidly dividing cells. Polyamines are
a requirement for the optimum growth and replication of
various cell types and are present in higher concentrations in
rapidly proliferating cells. The fact that polyamines can be
taken up by tissues from the circulation is known, since the
metabolism of labeled polyamines has been studied in vivo.
Tissues with a high demand for polyamines (e.g., prostate
tumors or normal but rapidly dividing cells) take up exogenous polyamines in increased amounts via a specific transport system. The high specific activity of polyamine transport
in tumor cells is thought to be associated with the inability of
biosynthetic enzymes to provide sufficient levels of
polyamines to sustain the rapid cell division. These "bioproduction" constraints are partially offset by scavenging
polyamines from exogenous sources.
Additional studies have indicated that polyanm10nium cations (PACs) have a very high DNA affinity, but are loosely
bound and can "read" DNA very rapidly because of their
otherwise unconstrained motion. These properties make
PACs and related polycations ideal fordrug delivery when the
drug needs to reach specific sites in the DNA. In short,
polyamine-containing conjugates can act as recognition elements for the polyamine uptake apparatus and may also
enhance DNA targeting via their electrostatic PAC-DNA
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interactions. These properties lay the foundation for a "valueadded" vectoring system as indicated in FIG. 3. In addition to
the demonstrated compounds, by attaching a polyamine
architecture (as example, the 4,4 triamine) onto a current drug
scaffold (e.g., doxorubicin), the potency and selectivity of the
drug may be increased (14, FIG. 4). Alternatively, a tetraamine scaffold could also provide enhanced abilities, (IS,
FIG. 4).
This invention identifies efficient polyamine vector architectures required to harness the polyamine transporter. This,
in tum, led to new drugs and drug delivery systems, which
target rapidly dividing cancer cells over normal resting cells
(e.g., melanoma cells over melanocytes, see Table 3). This is
a discovery of significant therapeutic value in the fight against
cancer. Moreover, this strategy has identified targeted antineoplastic agents, which are non-antibody based, as well as
structural elements, which can be attached to other drugs to
assist their entry into cells expressing a polyamine transporter.
The following examples are provided for the purpose of
illustration and not limitation.

triamine compounds Sb-g were formed in good yield. Impurities in 8 were removed by washing the solids with absolute
ethanol.
After repeated syntheses, it was found that S and 6 could be
used directly in subsequent steps to provide satisfactory
yields and purities of the target compounds 8. Therefore, as
long as adducts 4 and 7 were pure, one could avoid column
chromatography on the other intermediates, Sand 6.
As shown in Scheme 3, derivatives 4a-d were previously
converted to their respective N,0-bis-tosylates 9a-d. Displacement of the terminal tosylate by butanediamine provided the series, 1Oa-d in good yield. Derivatives 1Oa-d represent triamine systems containing two large aromatic motifs
and has one of the terminal amines sequestered as a sulfonamide.
As shown in Scheme 4, tetraamine derivatives 13a-i were
synthesized via intermediates 6, 11, and 12 using similar
methods as shown for Sb-g in Schemes 1 and 2 (FIGS.
2A-2B). How these structural perturbations influence the
cytotoxicity of the bioconjugate were evaluated via IC 50 and
K, determinations are listed in Tables 1 & 2.
FIG. 5 (Scheme S) provides an example of a synthetic
method to attach the polyamine vector onto an existing chemotherapeutic agent such as doxorubicin, 21. The use of an
antineoplastic agent conjugated to the appropriate polyamine
should provide enhanced antineoplastic activity. The synthetic methodology led to the synthesis of the N-Boc protected polyamine-doxorubicin conjugate 23 from which one
obtains the doxorubicin-4,4-triamine conjugate, 14. Coupiing an appropriate polyamine to other existing chemotherapeutic agents (e.g., mitoxantrone, anthramycin, camptothecin, vincristine or cis platin) should also provide an
enhanced chemotherapeutic agent.
As shown in FIG. 6A (Scheme 6), the aryl unit (Ar) was
varied to include a variety of common arylalkyl units
(ArCH 2 ). Using synthetic methods already described in
Scheme 2, compounds 26a-d were reacted with diamines to
form triamines 27a,b,d and Se, which contain R=arylalkyl.
Alternatively, they could be reacted with aminoalcohols,
tosylated and reacted with diamines to form the tetraamine
analogues similar to that outlined in FIG. 2C (Scheme 4) for
the synthesis of 13.
Internal modifications were also made to the aliphatic
spacer unit connecting the nitrogens. For example as shown in
FIG. 6B (Scheme 7), a hydroxy unit (30) or a cycloalkyl
spacer unit (31) were inserted synthetically using a similar
reaction of a diamine reacting with a tosylate (similar to how
compounds 8 were made in Scheme 2).
Overall, the synthetic method is modular and allows for a
variety of structural alterations to be introduced into the general architecture.
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Synthesis: As shown in FIG. 2A, Scheme 1, the reductive
amination of 1 to 4 was achieved in two steps via in situ
generation of the imine 3. A homologous series of imines
(3a-d) were prepared from 1 and different alcohols. Each
imine was then reduced to its respective amine 4 with NaBH4
in good yield without purification. Solvent removal by rotary
evaporation at 40-S0° C. facilitated imine formation and provided satisfactory yields of the 2° amines, 4a-d, (68-81 %)
after the two-step process. The 2° amines 4a-d were N-protected to form S using excess di-t-butyl dicarbonate, Boc 2 0.
Interestingly, compound Sb, which contained three methylene units, was unstable, even when it was stored at low temperature (0-S° C.) under nitrogen. This finding is in direct
contrast to Sa, Sc and Sd, which were stable at room temperature.
In the seemingly routine tosylation step, shown in Scheme
2, we were unable to obtain the desired compound 6a from the
N-Boc protected Sa. In addition, the impurities generated
during the formation of Sb greatly affected the tosylation
reaction. Nevertheless, tosylate 6b was isolated in lower yield
( S l % ), but was unstable to prolonged storage. In contrast,
tosylates 6c and 6d were prepared in higher yields (88%) and
were relatively stable. However, their respective colors and
1
HNMR spectra slowly changed during prolonged storage in
the refrigerator. Therefore, the tosylates 6 were best generated
and used as soon as possible. Alternatively, methanesulfonyl
chloride (i.e., mesyl chloride) can be used in lieu of tosyl
chloride to activate the alcohol subunit. The advantage to
using mesyl chloride is that it is readily removed by a IN
Na OH washing step. The yields using either sulfonylchloride
agent are comparable. However, the isolation of synthetic
intermediates, where OTs=O-mesyl instead of 0-tosyl in
Schemes 2-4 and Scheme 6, is more efficient and conducive
to scale-up processes.
As shown in Scheme 2, the tosylated compounds (6b-d)
were reacted with excess putrescine or 1,3-diaminopropane
to form six 1 N-Boc protected triamines 7b-g. These triamines
could be cleanly isolated, but were again unstable to prolonged storage at low temperature. Therefore, they were consumed in the next step immediately after purification. The
N-Boc groups of 7 were removed by 4N HCI, and the six
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Biological Evaluation. Three cell lines were chosen for bioassay. L1210 (mouse leukemia) cells were selected for comparison with the published IC50 and K, values determined for
a variety of polyamine substrates. In this regard both K, and
IC 50 values were measured in this line for comparison purposes. Chinese hamsterovary (CHO) cells were chosen along
with a mutant cell line (CHO-MG) in order to comment on
polyamine transporter affinity and cell selectivity. The CHOMG cell line is polyamine-transport deficient and was isolated after chronic selection for growth resistance to methylglyoxalbis (guanylhydrazone). For the purposes of this study,
the CHO-MG cell line represents cells with limited
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polyamine transport activity. In contrast, the parent CHO cell
line illustrates cell types with active polyamine transport.
Comparison of efficacy in these two lines provided an important screen to detect conjugate delivery via the polyamine
transporter, PAT. For example, a conjugate with high utilization of the transporter would be very toxic to CHO cells, but
less so to CHO-MG cells. Therefore, IC 50 determination in
these two CHO lines provided a relative ranking of delivery
via the PAT. In short, highly selective, vectored conjugates
would give high (CHO-MG/CHO) IC 50 ratios.
It is a well-known practice in pharmaceutical science to use
pharmaceutically acceptable acid salts of amine derivatives to
facilitate their long storage and dosing as aqueous solutions.
The examples listed in this invention are comprised of a
polyamine salt derived from a pharmaceutically acceptable
acid (e.g., HCl) with or without the use of a pharmaceutically
acceptable carrier (e.g., water). Such salts can be derived
from either inorganic or organic acids, including for example
hydrochloric, hydrobromic, acetic, citric, fumaric, maleic,
benzenesulfonic, and ascorbic acids. The pharmaceutical
compositions obtained by the combination of the carrier and
the polyamine salt will generally be used in a dosage necessary to elicit the desired biological effect. This includes its use
in an antineoplastic effective amount or in a lesser amount
when used in combination with other biologically active
agents.

TABLE I-continued
Biological Evaluation oftriamines Sb-g, N-tosyl derivativeslOa-d,
tetraamines 13a-i. homologues 27. and controls 30-35 in L1210 cells.

Cornpd
(tether)
10 32:Ant(octylene)
33:Ant(diethoxy)
34:Antbutanediarnine
15 35:Ant(Nbutyl)
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25

TABLE 1
Biological Evaluation oftriamines Sb-g, N-tosyl derivativeslOa-d,
tetraamines 13a-i. homologues 27. and controls 30-35 in L1210 cells.
L1210/
(L1210 +
DFMO)
IC 50 ratio

K; values
(µM)
L1210
cells

Cornpd
(tether)

L1210
IC 50 inµM

L1210 +
DFMO
IC 50 inµM

Sb (3, 3)
Sc (3, 4)
Sd (4, 3)
Se (4, 4)
Sf (5, 3)
Sg (5,4)
lOa (2,4)
!Ob (3, 4)
lOc (4,4)
lOd (5, 4)
13a (3, 3, 4)

1.S (±0.4)
0.7 (±0.3)
0.4 (±0.1)
0.3 (±0.04)
1.3 (±0.1)
0.4 (±0.1)
3.3 (±0.2)
6.3 (±0.5)
7.4 (±1.0)
6.2 (±0.3)
21.S (±3.2)

1.4 (±0.3)
0.3 (±0.1)
0.2 (±0.02)
0.15 (±0.1)
0.7 (±0.1)
0.3 (±0.1)
3.9 (±0.9)
7.7 (±1.1)
S.1 (±1.6)
6.9 (±0.S)
21.9 (±4.3)

1.3
2.3
2
2
1.9
1.3
0.9
O.S
0.9
0.9

13b (3, 4, 3)

19.5 (±2.S)

31.9 (±1.9)

0.6

13c (3, 4, 4)

9.S (±1.7)

5.1 (±0.6)

1.9

13d (3, 5, 4)

10.7 (±2.4)

7.2 (±0.1)

1.5

13e (4, 4, 3)

4.3 (±0.6)

0.6 (±0.2)

7.2

13f (4, 4, 4)

7.5 (±0.3)

1.6 (±0.3)

4.7

13g (5, 4, 3)

6.4 (±1.0)

2.1 (±0.7)

13h (5, 4, 4)

7.2 (±0.6)

3.S (±0.1)

1.9

13i (5, 5, 4)

7.1 (±1.2)

4.3 (±0.9)

1.7

27a: benzyl
(4,4)
27b: naphthyl
(4,4)
27d: pyrenyl
(4,4)
30:Anthydroxy amino
31:Ant(cyclohexyl)

36.3
(±S.4)
0.50
(±0.03)
0.40
(±0.02)
1.50
(±0.0S)
1.00
(±0.16)

421 (±27.1)

0.1

33.4 (±2.6)
2.5 (±0.3)
6.2 (±0.6)
1.S (±0.1)
5.0 (±0.6)
1.7 (±0.2)
ND
ND
ND
ND
0.107
(±0.013)
0.202
(±0.00S)
0.079
(±0.009)
0.090
(±0.006)
0.074
(±0.005)
0.051
(±0.006)
0.099
(±0.00S)
0.065
(±0.005)
0.064
(±0.005)
4.5 (±0.S)

0.43 (±0.02)

1.1

3.S (±0.5)

0.36 (±0.06)

1.1

2.9 (±0.3)

2.30 (±0.29)

0.7

12.5 (±1.2)

0.7 (±0.1)

1.4

3.S (±0.9)
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L1210
IC 50 inµM
3.00
(±0.07)
11.30
(±0.37)
6.30
(±0.26)
14.6 (±0.1)

L1210 +
DFMO
IC 50 inµM

L1210/
(L1210 +
DFMO)
IC 50 ratio

Ki values
(µM)
L1210
cells

4.60 (±0.12)

0.7

13.3 (±1.5)

17.0 (±0.61)

0.7

90.0 (±4.6)

9.78 (±0.42)

0.7

32.2 (±4.3)

21.9 (±3.6)

0.7

62.3 (±4.2)

As shown in Table 1, L1210 cells which were pretreated
with DFMO were more susceptible to the polyamine conjugates, which use the polyamine transporter (Sb-Sg). In contrast, DFMO pretreatment slightly reduced the potency of
systems, which do not use the transporter (10a-10d). These
conclusions were reached from the following two trends: a)
the IC 50 values were lower for the triamine series (Sb-Sg)
which use the transporter upon DFMO pretreatment and the
IC 50 values were higher for the triamine series which have
limited use of the transporter (lOa-d) upon DFMO pretreatment. As expected, the tetraamine systems 13a-i were also
effective in killing DFMO-pretreated cells. The homologous
series 27b, Se and 27d (in FIG. 6A, Scheme 6) revealed the
structural tolerance of the polyamine transporter to import
N-alkylaryl units of varying size and hydrophobicity.
Research has shown that the compounds of the invention,
mono-substituted N 1 -alkylaryl triamines, have enhanced
selectivity and cytotoxicity. The fact that Se and cyclohexyl
derivative 31 also had similar properties suggests that further
alterations of the polyamine chain can be accommodated by
the transporter. As expected, the control compounds 32-35
(FIG. 6) were all less cytotoxic than the vectored triamine
systems, S.
The K, values in Table 1 reflect the affinity of the polyamine
derivative for the transport apparatus on the cell surface. The
lower the K, value, the higher the affinity. Triamine-anthracene conjugates (which have a 4,4 triamine Se and 5,4
triamine Sg sequence) were preferred and demonstrated the
highest affinity for the polyamine transporter of the triamines
tested. The tetraamines 13 had the lowest IC 50 values and
reflected their superior affinity for the polyamine transporter.
However, their IC 50 values were typically higher than the
corresponding triamine systems, which means they are less
cytotoxic to cancer cells. This clearly illustrates that high
affinity for the polyamine transporter does not always translate into higher cytotoxicity. Thus it was surprising to find the
tetraamine derivatives were very selective as NMDA inhibitors.
TABLE2

60

Biological Evaluation oftriamines Sb-g, N-tosyl derivatives lOa-d and
tetraamines 13a-i, homologues 27, and controls 30-35, in the CHO
and CHO-MG cell lines.
Cornpd
(tether)

Sb (3, 3)
65 Sc (3, 4)
Sd (4, 3)

CHO-MG
IC 50 inµM

CHO
IC 50 inµM

CHO-MG/CHO
IC 50 ratio

3.4 (±0.5)
S.S (±1.2)
9.5 (±1.1)

1.9 (±0.4)
2.5 (±0.7)
0.4 (±0.1)

1.S
3.5
24
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TABLE 2-continued

TABLE3

Biological Evaluation oftriamines Sb-g, N-tosyl derivatives lOa-d and
tetraamines 13a-i, homologues 27, and controls 30-35, in the CHO
and CHO-MG cell lines.

Cell selectivity profile for Se and the control N-butyl derivative 35.

Cell Type
Compd
(tether)

CHO-MG
IC 50 in µM

CHO
IC 50 inµM

Se (4, 4)
Sf (5, 3)
Sg (5,4)
lOa (2,4)
!Ob (3, 4)
lOc (4,4)
lOd (5, 4)
13a (3, 3, 4)
13b (3, 4, 3)
13c (3, 4, 4)
13d (3, 5, 4)
13e (4, 4, 3)
13f (4, 4, 4)
13g (5, 4, 3)
13h (5, 4, 4)
13i (5, 5, 4)
27a: benzyl
(4,4)
27c: naphthyl
(4,4)
27d: pyrenyl
(4,4)
30: Ant-(4,3hydroxyamino)
31:Ant(cyclohexyl)
32:Ant(octylene)
33:Ant(diethoxy)
34:Antdiarnine
35:Ant
(N-butyl)

66.7 (±4.1)
10.1 (±1.2)
57.3 (±2.9)
7.1 (±0.4)
11.1 (±1.3)
10.6 (±1.9)
7.S (±1.9)
41.5 (±3.5)
75.7 (±7.3)
52.S (±2.6)
41.7 (±0.2)
2.S (±0.4)
33.2 (±1.7)
33.5 (±3.5)
30.S (±0.4)
5.7 (±1.6)
>1000

0.45 (±0.1)
4.1 (±0.5)
1.5 (±0.1)
5.1 (±0.6)
10.2 (±0.9)
10.4 (±1.6)
7.1 (±0.S)
44 (±0.0)
59.7 (±6.5)
31.2 (±7.3)
35 (±1.3)
4 (±1.4)
10.6 (±0.0)
lS (±3.5)
9.9 (±1.6)
4 (±0.S)
>1000

>100

0.6 (±0.2)

15.5 (±2.4)

0.46 (±0.05)

9.5 (±0.S)

9.1 (±0.4)

17.4 (±2.S)

2.5 (±0.5)

4.9 (±0.1)

4.9 (±0.2)

15.9 (±1.5)

12.6 (±0.6)

7.6 (±0.4)

7.7 (±0.5)

11.2 (±2.3)

10.5 (±2.0)

CHO-MG/CHO
IC 50 ratio
14S
2.5
3S
1.4
1.1
1.0
1.1
0.9
1.3
1.7
1.2
0.7
3.1
1.9
3.1
1.4
NA

B16 (melanoma)
B16 (melanoma)
B16 (melanoma)
10 Mel-A(normal
melanocyte)
Mel-A(normal
melanocyte)
Mel-A(normal
melanocyte)

20

25

7

30
1.3

1.1

As shown in Table 2, biological evaluation of triamines
Sb-g and 1Oa-d in CHO cells revealed that the 4,4-triamine Se
displays a nearly 150-fold preference for the CHO line containing PAT over CHO-MG, while the 3,3-triamine analogue
Sb preferred this line by only 1.S fold. Note: the entire tetraamine series 13 had, at best, only a 3 fold preference or
lower. However the tetraamine series 13 has been found to
have excellent use as an N-Methyl-D-Asparate (NMDA)
inhibitor. The results are set forth in Examples 4 and 5 and in
Tables 10 and 11. The naphthyl derivative 27b also had an
excellent selectivity profile with> 164 fold preference in killing cells with an active polyamine transport system. These
findings demonstrate that triamine conjugates (particularly Se
and 27b, which both used the 4,4 triamine vector) make
preferred cell targeting motifs. The effectiveness of the triamines is also reflected in the L1210 IC 50 results, wherein the
4,4-triamine Se and 5,4-triamine Sg showed a greater sensitivity to DFMO treatment. Therefore, the triamine systems
seem to give consistent data in all three cell lines.
Thus, the 4,4-triamine architecture represents a preferred
vectoring system, which upon attachment to a toxic agent
imparts high cell selectivity and low IC 50 values in the CHO
and L1210 cell lines (Tables 1 and 2). In short, one can
selectively deliver "large" toxic agents to tumor cells with
highly active polyamine transporters by using the proper
polyamine system for cell targeting.
An example of selectively targeting cancer cells (melanoma) with this strategy is illustrated in Table 3.

24h
4S h
72 h
24h

Ant-4,4-triamine Se
ICso(µM)
1.93
1.10
0.62
16.47

(±0.11)
(±0.07)
(±0.03)
(±1.95)

Ant-N-butylamine 35
ICso (µM)
19.25
21.31
20.39
44.30

(±2.76)
(±2.lS)
(±1.Sl)
(±9.14)

4S h

S.27 (±0.95)

32.SO (±4.64)

72 h

6.49 (±1.15)

15.00 (±3.73)

15

>164
34

Time

35

40

Many cancer cell lines are known to have high PAT activity,
and should be susceptible to this vectored chemotherapeutic
strategy. As shown in Table 3, the triamine-vectored Se analogue was 7.5-10.5 times more cytotoxic to melanoma B16
cells than the normal melanocytes, Mel-A (e.g. 6.49/
0.62=10.5). The Ant-N-butyl control 35 (FIG. 7), which has
been shown to not use the PAT, was only 0.7-2.3 fold more
potent. Since the respective cell doubling times are different,
IC 50 ratios (35/Se) for each cell type were also compared.
This alternative interpretation revealed that the presence of
the triamine vector in Se resulted in 10-32 fold higher cytotoxicity in B-16 cells, which have high PAT activity, than
control 35 (e.g., 24h: 19.25/1.93=10). In contrast, the triamine vector in Se resulted in only 2-4 fold higher cytotoxicity in Mel-A cells than35 (e.g. 24h: 44.3/16.47=2.7). These
results further support the proposed polyamine vector strategy as a viable means to target cancer cells over their healthy
counterparts.
With respect to the tetraamine systems, 13, the 4,4,4-tetraamine 13f and the 5,4,4-tetraamine 13h show enhanced
selectivity in killing cells with active polyamine transporters
(Table 2). The three-fold enhancement in cytotoxicity, while
not as remarkable as the related triamine systems, distinguished these two tetraamines as the best of the tetraamine
series studied.
Example 3
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Experimental Section
Materials. Silica gel (32-63 µm) was purchased from Scientific Adsorbents Incorporated. Chemical reagents were purchased either from the ACROS Chemical Co. or the Sigma
Chemical Co. and used without further purification. All solvents were distilled prior to use. 1 H NMR and 13 C NMR
spectra were recorded at 300 and 7 5 MHz, respectively. TLC
solvent systems are based on volume% and NH4 0H refers to
concentrated aqueous NH4 0H. All final compounds listed in
the Tables had satisfactory elemental analyses (a proof of
purity).
General Procedure for the Synthesis of N-(Anthracen-9-ylmethyl)amino Alcohols 4.
To a stirred solution of amino alcohol (12 mmol) in 25%
MeOH/CH 2 Cl 2 (10 mL) was added a solution of 9-anthraldehyde (lOmmol) in25% MeOH/CH 2 Cl 2 (10mL)underN2 .
The mixture was stirred at room temperature overnight until
the imine formation was complete (monitored by TLC). The
solvent was evaporated under vacuum to give the crude imine
as a bright green solid, which was used for reduction without
further purification.
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NaBH4 (30 mmol) was added in small portions to the
solution ofimine 1:1 CH 3 0H:CH 2 Cl 2 (20 mL) at 0° C. The
mixture was stirred at room temperature overnight, then concentrated under vacuum. The residue was dissolved in
CH 2 Cl 2 (SO mL), and washed three times with aq. Na2 C0 3
(pH 10, SO mL ). The organic layer was separated, dried over
anhydrous Na 2 S04 , filtered, and concentrated under vacuum.
The residue was purified by flash chromatography on silica
gel.

lH), 8.38 (br s, 2H), 8.01 (d, 2H), 7.43 (m, 4H), S.SO (br s,
2H), 3.30 (t, 2H), 3.00 (br s, 3H, including-OH), 1.S2 (br s,
9H).Anal. Calcd. forC 22 H 25 N0 3 : C, 7S.l9; H, 7.17; N, 3.98.
found. C, 7S.02, H, 7.13; N, 3.98.

2-[(Anthracen-9-ylmethyl)-amino ]ethanol, 4a. Bright yellow
solid; mp 116-118° C.; yield 77%; Rf=0.48, methanol/chloroform, 1:9; 1 HNMR(300MHz, CDC1 3 ): o8.40 (s, lH), 8.28
(d, 2H), 8.00 (d, 2H), 7.48 (m, 4H), 4.6.8 (s, 2H), 3.64 (t, 2H),
3.00 (t, 2H), 2.1 (br s, 2H); 13 C NMR: 0 131.7S, 131.44,
l30.4S, 129.47, 127.63, 126.48, 12S.23, 124.18, 61.12,
Sl.6S, 4S.4l; Anal. Calcd. for C 17 H 17 NO: C, 81.24; H, 6.82;
N, S.S7; found: C, 81.28; H, 6.83; N, S.S7; HRMS (FAB) m/z
calcd. for C 17 H 18 NO (M+Ht; 2S2.1388; found: 2S2.1381.
3-[(Anthracen-9-ylmethyl)-amino ]-propan-1-ol, 4b. Bright
yellow solid; mp 82-83° C.; yield 80%; Rf=O.Sl, methanol/
chloroform, 1:9; 1 HNMR (300MHz, CDC1 3 ): o8.40 (s, lH),
8.28 (d, 2H), 8.00 (d, 2H), 7.46 (m, 4H), 4.70 (s, 2H), 3.80 (t,
2H), 3.10 (t, 2H), 2.90 (br s, 2H), 1.78 (m, 2H); 13 C NMR: o
131.72, 130.98, 130.48, 129.48, 127.72, 126.S6, l2S.2S,
124.06, 64.6S, S0.83, 46.02, 31.14. Anal. Calcd. for
C 18H 19NO: C, 81.48; H, 7.22; N, S.28. Found: C, 81.20; H,
7.20; N, S.28. HRMS (FAB) m/z calcd. for C 18H 20NO
(M+Ht: 266.lS4S; found: 266.1S26.
4-[(Anthracen-9-ylmethyl)-amino ]-butan-1-ol, 4c. Bright
yellow solid; mp 87-88° C.; yield 81%; Rf=O.Sl, methanol/
chloroform, 1:9; 1 H NMR (300 MHz, CDC1 3 ) o8.40 (s, lH),
8.26 (d, 2H), 8.00 (d, 2H), 7.49 (m, 4H), 4.68 (s, 2H), 3.SO (t,
2H),2.90(t,2H), l.6S (brs;4H); 13 CNMR: o131.74, 130.73,
130.48, 129.Sl, 127.82, 126.64, 12S.30, 123.96, 62.89,
SO.S8, 4S.72, 32.72, 29.13. Anal. Calcd. for C 19H 21 NO: C,
81.68; H, 7.S8; N, S.01. found: C, 81.63; H, 7.6S; N, S.10.
HRMS (FAB) m/z calcd. for: C 19H 22 NO (M+Ht: 280.1701;
found: 280.1679.
S-[(Anthracen-9-ylmethyl)-amino ]-pentan-1-ol, 4d. Bright
yellow solid; mp 76-77° C.; yield 68%; Rf=0.26, methanol/
chloroform (S:9S); 1 HNMR (CDC1 3 ): o8.38 (s, lH), 8.27 (d,
2H), 7.98 (d, 2H), 7.4S (m, 4H), 4.6S (s, 2H), 3.SO (t, 2H), 2.82
(t, 2H), 1.78 (br s, 2H), I.SO (m, 4H), 1.40 (m, 2H); 13 C NMR
(CDC1 3 ): o 131.89, 131.77, 130.48, 129.44, 127.46, 126.40,
12S.19, 124.29, 62.68, S0.60, 4S.96, 32.68, 29.91, 23.67.
Anal. Calcd. for C 20 H 23 NO: C, 81.87; H, 7.91; N, 4.77.
found: C, 81.89; H, 7.99; N, 4.86. HRMS (FAB) m/z calcd.
for C 20 H 24NO (M+Ht; 294.18S8; found: 294.183S.
The General Procedure for the N-Boc, protection ofN-(Anthracen-9-ylmethyl)-amino alcohols 4 to give S. The solution
ofN-(anthracen-9-ylmethyl)-amino alcohol (S mmol) in 20
mL of pyridine-methanol (l:S v/v) was stirred at 0° C. for 10
min. A solution of di-tert-butyl dicarbonate (7.S mmol) in
methanol (S mL) was added dropwise over ten minutes. The
temperature was allowed to rise to room temperature and the
reaction was stirred overnight. The mixture was evaporated to
dryness under reduced pressure. The residue was dissolved in
methylene chloride, and washed with deionized water several
times. The organic layer was separated, dried over anhydrous
Na 2 S04 , filtered, and concentrated under vacuum. The residue was purified by flash chromatography on silica gel.
Anthracen-9-ylmethyl-(2-hydroxy-ethyl) carbamic acid tertbutyl ester, Sa. Pale yellow solid; mp 131-132° C.; yield 84%;
Rf=0.21 (acetone/hexane 1:4); 1 H NMR (CDC1 3 ): o 8.43 (s,
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Anthracen-9-ylmethyl-(3-hydroxy-propyl) carbamic acid
tert-butyl ester, Sb. Unstable pale yellow solid; yield 90%, Rf
0.23(acetone/hexane1:4); 1 HNMR(CDC1 3 ): o8.42 (s, lH),
8.36 (d, 2H), 8.02 (d, 2H), 7.S2 (m, 4H), S.SO (br s, 2H), 3.2S
(br s, 2H), 3.10 (br s, 2H), 1.62 (m, llH). HRMS (FAB):
calcd. forC 23 H 28 N0 3 (M+Ht; 366.2069; Found: 366.2067.
Anthracen-9-ylmethyl-(4-hydroxy-butyl) carbamic acid tertbutyl ester, Sc. Pale yellow solid; mp 113-114° C.; yield 88%;
Rf=0.13 (acetone/hexane 12:88); 1 H NMR (CDC1 3 ): o 8.42
(s, lH), 8.39 (d, 2H), 8.01 (d, 2H), 7.S2 (m, 4H), S.SO (br s,
2H), 3.2S (t, 2H), 2.80 (brs, 2H), 1.60 (br s, 9H), 1.20 (m, 4H).
13
C NMR: o lSS.88, 131.S2, 131.48, 129.4S, 128.99, 126.S3,
l2S.22, 124.32, 80.08, 62.3S, 44.S4, 41.28, 30.0S, 28.94
(3C), 24.99.Anal. Calcd. forC 24 H 29N0 3 : C, 7S.96; H, 7.70;
N, 3.69. found: C, 76.04; H, 7.64; N, 3.68. HRMS (FAB):
calcd. for C 24 H 29 N0 3 Na (M+Nat: 402.204S; found:
402.2070.
Anthracen-9-ylmethyl-(S-hydroxy-pentyl) carbamic acid
tert-butyl ester, Sd. Pale yellow solid; mp 12S-126° C.; yield
84%; Rf=0.28 (acetone/hexane 1:4); 1 H NMR (CDC1 3 ): o
8.44 (s, lH), 8.41(d,2H), 8.0S (d, 2H), 7.SS (m, 4H), S.S6 (br
s, 2H), 3.38 (t, 2H), 2.82 (br s, 2H), 1.64 (br s, 9H), l.2S (m,
4H), 0.98 (m, 2H); 13 C NMR: 0 lSS.97, 131.S6, 131.S3,
129.43, 128.34, 126.Sl, 12S.23, 124.43, 79.94, 62.8S, 44.84,
41:41, 32.33, 28.96 (3C), 28.43, 23.14. Anal Calcd. for
C 25 H 31 N0 3 : C, 76.30; H, 7.94; N, 3.S6. found: C, 76.29; H,
7.96; N, 3.67. HRMS (FAB): calcd. forC 25 H 32N0 3 (M+Ht:
394.2382; found: 394.238S.
General Procedure for the tosylation ofN-Boc protected (anthracen-9-ylmethyl)-amino alcohols 4 to give 9. A solution of
the N-Boc protected (anthracen-9-ylmethyl)-amino alcohol
(S mmol) in 20 mL dry pyridine was stirred at 0° C. for 10
min. p-Toluenesulfonyl chloride (TsCl, 7 .S mmol) was added
in small portions over 30 min. The mixture was stirred for an
additional hour and the reaction flask was placed in a refrigerator (0-S° C.) overnight. The mixture was poured into 200
mL ofice-water, and a hemi-solid (or viscous liquid) typically
precipitated (or separated). After decanting off the upper
layer, the residue was dissolved in methylene chloride and
washed several times with deionized water. The organic layer
was separated, dried over anhydrous Na 2 S04 , filtered and
concentrated under vacuum. The residue was purified by flash
chromatography on silica gel.
Toluene-4-sulfonic acid 3-(anthracen-9-ylmethyl-tert-butoxycarbonyl-amino )-propyl ester, 9b. Unstable bright yellow viscous liquid, yield Sl %; Rf=0.21 (acetone/hexane 1:4).
1
H NMR (CDC1 3 ): o8.42 (s, lH), 8.39 (d, 2H), 8.0S (d, 2H),
7.S8 (m, 6H), 7.21 (d, 2H), S.46 (s, 2H), 3.63 (t, 2H), 2.82 (t,
2H), 2.41 (s, 3H), 1.64 (br s, llH). HRMS (FAB): calcd. for
C 25 H 26N0 3 S (M+2H-Boct; 420.1633; found: 420.1642.
Toluene-4-sulfonic acid 4-(anthracen-9-ylmethyl-tert-butoxycarbonyl-amino )-butyl ester, 9c. Pale yellow viscous liquid; yield 88%; Rf=0.38, acetone/hexane 1:3; 1 H NMR
(CDC1 3 ): o 8.42 (s, lH), 8.37 (d, 2H), 8.00 (d, 2H), 7.62 (d,
2H), 7.48 (m, 4H), 7.22 (d, 2H), S.46 (s, 2H), 3.63 (t, 2H), 2.77
(br s, 2H), 2.40 (s, 3H), 1.48 (br s, 9H), 1.20 (br s, 4H); Anal.
Calcd. forC 31 H 35 N0 5 S O.SH 2 0: C, 68.61; H, 6.69; N, 2.S8.
found: C, 68.74; H, 6.S7; N, 2.SS. HRMS: calcd. for
C 31 H 35 N0 5 S M+: S33.2236; found: S33.2236.
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Toluene-4-sulfonic acid 5-(anthracen-9-ylmethyl-tert-butoxycarbonyl-amino )-pentyl ester, 9d. Pale yellow viscous
liquid; yield SS%; Rf=0.25, acetone/hexane 1:4; 1H NMR
(CDC1 3): o S.42 (s, lH), S.36 (d, 2H), S.00 (d, 2H), 7.63 (d,
2H), 7.46 (m, 4H), 7.22 (d, 2H), 5.47 (s, 2H), 3.73 (br s, 2H),
2.76 (br s, 2H), 2.40 (s, 3H), 1.4S (br s, 9H), 1.24 (br s, 2H),
1.20 (br s, 2H), 0.93 (br s, 2H); Anal. Calcd. for C 32 H37 N0 5 S
0.5H 20: C, 69.04; H, 6.SS; N, 2.52. found: C, 69.15; H, 6.75;
N, 2.57. HRMS (FAB): calcd. for C 32 H38 N0 5 S (M+Ht:
54S.2471; found: 54S.2501.
General Procedure for the preparation of the N 1-Boc pro-

N-(3-Amino-propyl)-N-anthracen-9-ylmethyl-butane-1,4diamine, trihydrochloride Sd. Bright yellow solid, yield 95%.
1HNMR (DMSO-d +D 0): oS.SO (s, lH), S.42 (d, 2H), S.20
6 2
(d, 2H), 7.73 (t, 2H), 7.64 (t, 2H), 5.23 (s, 2H), 3.30 (t, 2H),
2.99 (m, 6H), 2.00 (m, 2H), 1.SO (m, 4H). 13 C NMR (D 20): o
130.65, 130.37, 130.04, 129.4S, 127.70, 125.51, 122.49,
120.30, 47.lS (2C), 44.7S, 42.79, 36.Sl, 24.04, 23.14, 22.99.
Anal. Calcd. for C 22 H32 Cl 3N 3: C, 59.40; H, 7.25; N, 9.45.
found: C, 59.4S; H, 7.07; N, 9.30. HRMS (FAB): calcd. for
C 22 H32Cl 2N 3 (M+H-HClt; 40S.1973; found: 40S.195S.

tected-N1-(Anthracen-9-ylmethyl)-triamines, 7. The tosylated products 6 (1 mmol) and 1,4-diaminobutane or 1,3diaminepropane (10 mmol) were dissolved in acetonitrile (10
mL ), then stirred at 7 5° C. under N 2 overnight. After checking
forthe disappearance of the tosylate by TLC, the solution was
concentrated under reduced pressure. The residue was dissolved in CH 2Cl 2 (20 mL) and washed three times with saturated aqueous sodium carbonate. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and
concentrated under vacuum. The residue was purified by flash
chromatography on silica gel. The purified products were
used immediately for next step (BOC deprotection). The isolated yields ranged between 59-75%.
General Procedure for the preparation of the N 1-(Anthracen9-ylmethyl)-triamines, S. The N 1-Boc protected-N 1-(anthracen-9-ylmethyl)-triamine 7 (0.5 mmol) was dissolved in ethanol (5 mL ), and stirred at 0° C. for 10 min. 4 N aq. HCl (S mL)
was added dropwise at 0° C. The mixture was stirred at room
temperature overnight. The solution was then concentrated
under reduced pressure (while maintaining the water bath on
the rotary evaporator below 60° C.) and a bright yellow solid
precipitated. The solids were washed several times with absolute ethanol and provided the pure target compounds. The 1H
NMR spectra of polyamine conjugates were measured in 0.5
mL DMSO-d 6 and 3 drops ofD 20. The use ofDMSO-d 6/D 20
mixtures resulted in better spectral resolution (compared to
using pure D 20 as solvent). The 13 C NMR spectra of the
triamines were measured in D20 to avoid the interference of
DMSO carbon signals. The listed amines are all in their HCl
salt form.
N-(3-Amino-propyl)-N-anthracen-9-ylmethyl-propane-1,3diamine, trihydrochloride Sb. Bright yellow solid, yield 9S%.
1HNMR(DMSO-d +D 0): oS.SO (s, lH), S.40 (d, 2H), S.22
6 2
(d, 2H), 7.75 (t, 2H), 7.62 (t, 2H), 5.23 (s, 2H), 3.40 (t, 2H),
4
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122.4S, 120.06, 44.91, 44.S2, 44.75, 43.0S, 36.74, 23.9S,
22.93. Anal. Calcd. for C 21 H30Cl 3N 3: C, 5S.54; H, 7.02; N,
9.75. found: C, 5S.27; H, 6.90; N, 9.69. HRMS (FAB): calcd.
for C 21 H30 Cl 2N 3 (M+H-HClt; 394.1S17; found:
394.1S06.
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N1-{ 3-[ (Anthracen-9-ylmethyl)-amino ]-propyl }-butane-I,
4-diamine, trihydrochloride Sc. Bright yellow solid, yield
9S%. 1H NMR (DMSO-d 6+D 20): o S.SO (s, lH), S.42 (d,
2H), S.20 (d, 2H), 7.72 (t, 2H), 7.62 (t, 2H), 5.23 (s, 2H), 3.42
(t, 2H), 3.05 (t, 2H), 2.9S (t, 2H), 2.S2 (t, 2H), 2.20 (br s, 2H),
1.71 (br s, 4H). 13 C NMR (D20): o 130.57, 130.41, 130.01,
129.45, 127.71, 125.4S, 122.46, 119.9S, 47.27, 44.76, 44.66,
43.01, 39.03, 24.16, 23.00, 22.92. Anal. Calcd. for
C 22 H32Cl 3N 3 0.6H 20: C, 57.99; H, 7.34; N, 9.22. found: C,
5S.OO; H, 7.36; N, 9.20 HRMS (FAB): calcd. for
C 22 H32Cl 2N 3 (M+H-HClt; 40S.1973; found: 40S.1950.

60

65

N-( 4-Amino-butyl)-N-anthracen-9-ylmethyl-butane-1,4-diamine, trihydrochloride Se. Bright yellow solid, yield 91 %.
1HNMR (DMSO-d +D 0): oS.SO (s, lH), S.42 (d, 2H), S.20
6 2
(d, 2H), 7.70 (t, 2H), 7.61 (t, 2H), 5.23 (s, 2H), 3.30 (t, 2H),
2.93 (m, 4H), 2.S2 (t, 2H), 1.7S-1.60 (m, SH). 13 C NMR
(D 20): o 130.62, 130.32, 130.01, 129.45, 127.67, 125.4S,
122.4S, 120.37, 47.17, 47.11, 47.00, 42.76, 39.03, 24.19,
23.14, 23.02 (2C).Anal. Calcd. forC 23 H34Cl 3N 3 O.SH 20: C,
5S.37; H, 7.5S; N, S.SS. found: C, 5S.39; H, 7.36; N, S.76.
HRMS (FAB): calcd. for C 23 H32N 3 (M+H-3HClt:
350.2590; found: 350.2611.
N-(3-Amino-propyl)-N-anthracen-9-ylmethyl-pentane-1,5diamine, trihydrochloride Sf. Bright yellow solid, yield S6%.
1HNMR (DMSO-d +D 0): oS.SO (s, lH), S.42 (d, 2H), S.20
6 2
(d, 2H), 7.72 (t, 2H), 7.64 (t, 2H), 5.22 (s, 2H), 3.2S (t, 2H),
2.99 (m, 6H), 2.00 (m, 2H), 1.SO (m, 2H), 1.72 (m, 2H), 1.42
(m, 2H); 13 C NMR (D20): o 130.54, 130.23, 129.91, 129.39,
127.60, 125.42, 122.42, 120.30, 47.62, 47.54, 44.69, 42.56,
36.SO, 25.2S, 25.22, 24.01, 23.20. Anal. Calcd. for
C 23 H34Cl 3N 3 0.2H 20: C, 59.73; H, 7.50; N, 9.09. found: C,
59.71; H, 7.40.; N, 9.06. HRMS (FAB): calcd. for
C 23 H34Cl 2N 3 (M+H-HClt; 422.2130; found: 422.2106.
N-( 4-Amino-butyl)-N-anthracen-9-ylmethyl-pentane-1,5diamine, trihydrochloride Sg. Bright yellow solid, yield SS%.
1HNMR (DMSO-d +D 0): oS.SO (s, lH), S.42 (d, 2H), S.20
6 2
(d, 2H), 7.73 (t, 2H), 7.64 (t, 2H), 5.23 (s, 2H), 3.26 (t, 2H),
2.93 (br s, 4H), 2.S2 (t, 2H), 2.00 (m, 2H), 1.SO (m, 2H), 1.72
(br s, 4H), 1.42 (m, 2H); 13 C NMR (D 20): o 130.49, 130.21,
129.S9, 129.3S, 127.61, 125.41, 122.42, 120.23, 47.51,
47.46, 47.07, 42.50, 39.06, 25.29, 25.19, 24.22, 23.20, 23.04.
Anal. Calcd. for C 24H36 Cl 3N 3: C, 60.95; H, 7.67; N, S.S9.
found: C, 60.74; H, 7.63; N, S.79. HRMS (FAB): calcd. for
C 24 H36Cl 2N 3 (M+H-HClt; 436.22S6; found: 436.22S9.
General Procedure forthe Substitution of the Tosylated Compounds with the amino alcohols or diamines (Preparation of
11or13). The tosylated products (compounds 6 or 12) (1
mmol) and co-amino-a-alcohols (5 mmol) (or diamines when
making 13) were dissolved in acetonitrile (10 mL), then
stirred at 75° C. under N 2 overnight. After checking the disappearance of tosylated products by TLC, the solution was
concentrated under reduced pressure. The residue was dissolved in CH 2Cl 2 (20 mL ), washed three times with saturated
aqueous sodium carbonate. The organic layer was separated,
dried with anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by flash colunm on silica gel. The purified products 11 were used for next
step immediately. During the synthesis of 13, an intermediate
compound (13x), which still contained two N-BOC groups
was isolated and immediately converted to 13 as described
below.
General Procedure for the Amino Group Deprotection
(Preparation of 13) The N-Boc protected N 1-(Anthracen-9ylmethyl)-tetraamines (13x, 0.5 mmol) were dissolved in
ethanol (5 mL), andstirredat0° C. for lOmin. 4NHC1 (SmL)

US 7,728,040 Bl

19

20

then added dropwise at 0° C. The mixture was stirred at room
temperature overnight. After that the solution was concentrated under reduced pressure below 60° C., and the bright
yellow solid precipitated. The solid was washed with 100%
ethanol for several times and to give the pure target compounds 13.

yellow solid; yield S6%; 1 H NMR: SS.79 (s, lH), S.40 (d,
2H), S.19 (d, 2H), 7.6S (t, 2H), 7.60 (t, 2H), 5.21(s,2H), 3.24
(br s, 2H), 2.92 (br s, SH), 2.S4 (br s, 2H), 1.SO (br s, 2H), 1.64
(br s, !OH). 13 CNMR: 0130.75, 130.46, 130.14, 129.53,
127.77, 125.57, 122.57, 120.45, 47.24, 47.20, 47.14 (2C),
47.0S, 42.SS, 39.09, 24.26, 23.lS, 23.12 (2C), 23.10, 23.06.
Anal. Calcd. for C 27 H44Cl 4 N4 Cl 2 0: C, 56.S9; H, 7.S5; N,
9.S3. found: C, 56.S2; H, 7.S7; N, 9.76. HRMS (FAB): calcd.
for C 27 H41 N4

5

N1-{ 3-[3-(Anthracen-9-ylmethyl)-amino ]-propylamino }butane-1,4-diamine Tetrahydrochloride (13a) Bright yellow
solid; yield 96%; 1 H NMR: oS.72 (s, lH), S.2S (d, 2H), S.16
(d, 2H), 7.64 (t, 2H), 7.5S (t, 2H), 5.20 (br s, 2H), 3.3S (br s,
2H), 3.00 (m, SH), 2.S4 (br s, 2H), 2.12 (br s, 2H), 2.00 (br s,
2H), 1.62 (br s, 4H). 13 CNMR: o 130.73, 130.54, 130.17,
129.55, 127.S2, 125.59, 122.57, 120.17, 47.3S, 44.91 (2C),
44.S3, 44.70, 43.19, 39.11, 24.25, 23.09, 22.99 (2C). Anal.
Calcd. for C 25 H40 Cl4 N4 H 2 0: C, 53.96; H, 7.61; N, 10.07.
found: C, 53.S9; H, 7.62; N, 10.0S. HRMS (FAB): calcd. for
C 25 H37N4 (M+H-4HClt: 393.3013; found: 393.3020
N-(3-Amino-propyl)-N-{3-[(anthracen-9-ylmethyl)amino ]-propyl }-butane-1,4-diamine
Tetrahydrochloride
(13b) Bright yellow solid; yield 91 %; 1 H NMR: o S.73 (s,
lH), S.2S (d, 2H), S.17 (d, 2H), 7.64 (t, 2H), 7.5S (t, 2H), 5.lS
(s, 2H), 3.30 (t, 2H), 2.96 (m, !OH), 2.10 (m, 2H), 1.90 (m,
2H), 1.60 (br s, 4H). 13 CNMR: 5130.70, 130.51, 130.13,
129.51, 127.77, 125.55, 122.54, 120.15, 47.25 (2C), 44.Sl
(2C), 44.71, 43.12, 36.Sl, 24.06, 23.05 (2C), 22.97. Anal.
Calcd. forC 25 H40 Cl4 N4 0.4H 2 0: C, 55.03; H, 7.54; N, 10.27.
found: C, 55.02; H, 7.49; N, 10.lS. HRMS (FAB): calcd. for
C 25 H37N4 (M+H-4HClt: 393.3013; found: 393.301S
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(M+H-4HClt; 421.3326; found: 421.3310 N-[4-(3-Aminopropylamino )-butyl]-N-anthracen-9-ylmethyl-pentane-1,5diamine Tetrahydrochloride (13g) Bright yellow solid; yield
SS%; 1 HNMR: 5S.79 (s, lH), S.40 (d, 2H), S.19 (d, 2H), 7.66
(t, 2H), 7.60 (t, 2H), 5.20 (s, 2H), 3.22 (t, 2H), 2.90 (m, !OH),
1.92 (m, 2H), 1.66 (m, SH), 1.40 (m, 2H). 13 CNMR: 5130.70,
130.36, 130.07, 129.49, 127.72, 125.54, 122.53, 120.50,
47.64, 47.53, 47.30, 47.05, 44.S2, 42.69, 36.S4, 25.36, 25.2S,
24.07, 23.27, 23.11, 23.09. Anal. Calcd. for C 27 H44 Cl4 N4
0.5H 2 0: C, 56.35; H, 7.SS; N, 9.74. found: C, 56.36; H, 7.76;
N, 9.77. HRMS (FAB): calcd. for C 27 H41 N4 (M+H-4HClt:
421.3326; found: 421.3319

N-[ 4-( 4-Amino-butylamino )-butyl]-N-anthracen-9-ylmethyl-pentane-1,5-diamine Tetrahydrochloride (13h) Bright
25
yellow solid; yield 92%; 1 HNMR: 5S.7S (s, lH,), S.39 (d,
2H), S.lS (d, 2H), 7.66 (t, 2H), 7.60 (t, 2H), 5.20 (s, 2H), 3.22
(t, 2H), 2.SS (br s, SH), 2.SO (m, 2H), 1.74 (m, 2H), 1.62 (br
s, !OH), 1.40 (m, 2H). 13 CNMR: o 130.70, 130.36, 130.07,
129.49, 127.72, 125.54, 122.53, 120.50, 47.64, 47.53, 47.20,
30
N-(4-Amino-butyl)-N-{ 3-[ (anthracen-9-ylmethyl)-amino ]47.14, 47.06, 42.70, 39.0S, 25.36, 25.2S, 24.24, 23.27, 23.12
(2C), 23.0S.Anal. Calcd. forC 28 H46 Cl 4 N4 0.6H 2 0: C, 56.SS;
propyl }-butane-4,4-diamine Tetrahydrochloride (13c) Bright
yellow solid; yield 95%; 1 H NMR: o S.SO (s, lH), S.40 (d,
H, S.05; N, 9.4S. found: C, 56.S9; H, 7.92; N, 9.40. HRMS
2H), S.19 (d, 2H), 7.66 (t, 2H), 7.60 (t, 2H), 5.21(s,2H), 3.40
(FAB): calcd. forC 28 H43 N4 (M+H-4HClt: 435.34S2; found:
435.3477.
(t, 2H), 3.02 (t, 2H), 2.92 (m, 6H), 2.S2 (t, 2H), 2.11 (m, 2H),
35
1.62 (m, SH). 13 CNMR: o 130.S5, 130.62, 130.29, 129.57,
N-[5-( 4-Amino-butylamino )-pentyl]-N-anthracen-9-ylm127.S6, 125.64, 122.61, 120.3S, 47.26, 47.lS, 47.10, 44.S6,
ethyl-pentane-1,5-diamine Tetrahydrochloride (13i) Bright
44.72, 43.25, 39.06, 24.23, 23.07 (2C), 22.99. Anal. Calcd.
yellow solid; yield 99%; 1 H NMR: 5S.70 (s, lH), S.2S (d,
for C 26 H42 Cl 4 N4 1.2H2 0: C, 54.40; H, 7.SO; N, 9.76. found:
2H), S.13 (d, 2H), 7.66 (t, 2H), 7.56 (t, 2H), 5.24 (s, 2H), 3.16
C, 54.43; H, 7.67; N, 9.79. HRMS (FAB): calcd. for
40 (t, 2H), 2.SS (m, !OH), 1.70 (m, 2H), 1.5S (m, !OH), 1.32 (m,
C 26 H39N4 (M+H-4HClt: 407.3175; found: 407.3165
4H). 13 C NMR: 5130.69, 130.35, 130.06, 129.49, 127.70,
N-(4-Amino-butyl)-N-{3-[(anthracen-9-ylmethyl)-amino]125.52, 122.52, 120.50, 47.62, 47.56, 47.4S, 47.44, 47.11,
propyl}-pentane-1,5-diamine Tetrahydrochloride (13d)
42.67, 39.0S, 25.42 (2C), 25.34, 25.27, 24.25, 23.27, 23.21,
23.07. Anal. Calcd. for C 29 H48 Cl4 N4 0.7H 2 0: C, 57.37; H,
Bright yellow solid; yield SS%; 1 HNMR: oS.70 (s, lH), S.2S
(d, 2H), S.15 (d, 2H), 7.63 (t, 2H), 7.5S (t, 2H), 5.20 (s, 2H), 45 S.20; N, 9.23. found: C, 57.27; H, S.11; N, 9.14. HRMS
3.3S (t, 2H), 3.01(t,2H), 2.90 (m, SH), 2.11(m,2H), 1.62 (br
(FAB): calcd. forC 29 H45 N4 (M+H-4HClt: 449.3644; found:
s, SH), 1.2S (m, 2H). 13 CNMR: o 130.71, 130.52, 130.14,
449.3650.
129.53, 127.SO, 125.57, 122.55, 120.16, 47.70, 47.54, 47.12,
Synthesis of 23. A mixture of doxorubicin 21 (1 equiv.) and
44.S4, 44.65, 43.13, 39.10, 25.39 (2C), 24.26, 23.16, 23.0S,
{4-[ tert-butoxycarbonyl-(4-oxo-butyl)-amino ]-butyl }-car22.97. Anal. Calcd. for C 27 H44 Cl4 N4 1.0H2 0: C, 55.4S; H, 50
bamic acid tert-butyl ester 20 (2 equiv.) in 25% methanol7.93; N, 9.59. found: C, 55.52; H, 7.97; N, 9.56. HRMS
dichloromethane (5 mL) were stirred at 0° C. for several
(FAB): calcd. forC 22 H41 N4 (M+H-4HClt: 421.3326; found:
minutes, then added IM NaBH 3 CN in THF (0.67 equiv.)
421.3327
(FIG. 5). After checking the disappearance of doxorubicin by
N-[ 4-(3-Amino-propylamino )-butyl]-N-anthracen-9-ylmTLC and a new less polar spot formed, the solution was
55
ethyl-butane-1,4-diamine Tetrahydrochloride (13e) Bright
concentrated and the residue was purified by preparative
1
yellow solid; yield 94%; H NMR: o S.79 (s, lH), S.40 (d,
TLC. Rf=0.3S (10% methanol-chloroform) to give 23. Com2H), S.19 (d, 2H), 7.6S (t, 2H), 7.60 (t, 2H), 5.21(s,2H), 3.2S
pound 23: 1 H NMR (CDC1 3 ) o S.05 (d, lH, Hl), 7.SO (t, lH,
(t, 2H), 2.92 (m, !OH), 1.92 (m, 2H), 1.SO (m, 2H), 1.70 (br s,
H2), 7.41 (d, lH, H3), 5.52 (m, lH, Hl'), 5.33 (m, lH, H7),
6H). 13 CNMR: 6130.69, 130.41, 130.09, 129.49, 127.73,
4.77 (m, 2H, H14), 4.5S (m, lH, NHCO), 4.10 (s, 3H, OCH 3 ),
60
125.53, 122.52, 120.37, 47.2S, 47.20, 47.12, 47.06, 44.Sl,
3.9S (q, lH, HS'), 161 (m, lH, H4'), 3.29 (d, lH, HlO),
42.S2, 36.S2, 24.05, 23.15, 23.0S (2C), 23.01. Anal. Calcd.
3.22-3.02 (m, 7H, HlO, 3xCH2 ), 2.79 (m, lH, H3'), 2.59 (m,
for C 26 H42 Cl 4 N4 0.5H 2 0: C, 55.62; H, 7.72; N, 9.9S. found:
2H, NCH 2 ), 2.40 (d, lH, HS), 2.16 (dd, lH, HS), 1.75 (m, lH,
C, 55.62; H, 7.55; N, 9.S5. HRMS (FAB): calcd. for
H2'), 1.70-1.35 (m, 30H, H2', SxCH 2 , 6xCH 3 ).
C 26 H39N4 (M+H-4HClt: 407.3169; found: 407.3166
65 4-(N-Benzylamino)-butan-l-ol (24a). Pale yellow liquid:
N-[ 4-( 4-Amino-butylamino )-butyl]-N-anthracen-9-ylmyield S9%; Rf=0.34, methanol/chloroform, 1:4); 1 H NMR
ethyl-butane-1,4-diamine Tetrahydrochloride (131) Bright
(300 MHz, CDC1 3 ) o7.29 (brs, 5H), 3.77 (s, 2H), 3.59 (t, 2H),
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2.6S (t, 2H), 1.65 (brs, 4H); 13 C NMR: o 13S.S, 12S.4 (2C),
12S.1(2C),127.1, 62.5, 53.7, 49.1, 32.4, 2S.5; HRMS (FAB)
m/z calcd. for C 11 H 18 NO (M+Ht; 1S0.13SS; found:
1S0.13S9.
N-(Naphthalen-l-ylmethyl)-4-amino-butan-1-ol (24b ). Dark
yellow liquid; yield 93.6%; Rf=0.54, methanol/chloroform,
1:4); 1H NMR (300 MHz, CDC1 3) o S.02 (d, lH), 7.S5 (d,
lH), 7.76 (d, lH), 7.47 (m, 4H), 4.23 (s, 2H), 3.5S (t, 2H), 2.79
(t, 2H), 2.51 (brs, 2H), 1.6S (brs, 4H); 13 C NMR: o 134.5,
133.6, 131.3, 12S.6, 127.S, 126.2, 126.1, 125.5, 125.2, 122.9,
62.4, 51.0, 49.6, 32.1, 2S.3; HRMS m/z calcd. for C 15 H 19NO
(M±): 229.1467; found: 229.1477.
4-[(Anthracen-9-ylmethyl)-amino ]-butan-1-ol (24c ). See 4c
above.
4-[(Pyren-1-ylmethyl)-amino]-butan-1-ol (24d). White
solid; yield 94%. 1H NMR (300 MHz, CDC1 3): oS.24 (d, 2H),
S.13 (m, 4H), 7.96 (m, 4H), 4.42 (s, 2H), 3.56 (t, 2H), 2.S2 (t,
2H), 1.64 (brs, 4H). 13 C NMR (CDC1 3): 132.4, 131.0, 130.6,
130.5, 12S.7, 127.7, 127.2, 127.0 (2C), 125.7, 125.0, 124.9,
124.S, 124.6 (2C), 122.4, 62.6, 51.3, 49.6, 32.3, 2S.6. HRMS
(FAB): calcd. for C 21 H 22 NO (M+Ht: 304.1701; found:
304.1701.N-(4-Amino-butyl)-N'-benzene-1-ylmethyl-butane-1,4-diamine Trihydrochloride (27a). White solid; yield
73%. 1H NMR (300 MHz, DMSO+D 20): o 7.47 (br s, 2H),
7.41 (br s, 3H), 4.09 (s, 2H), 2.SS (br s, 6H), 2.7S (br s, 2H),
1.63 (br s, SH). 13 C NMR (D20): 130.7, 129.9 (2C), 129.S,
129.4 (2C), 51.3, 47.13, 47.07, 46.5, 39.0, 24.2, 23.1, 23.0
(2C); HRMS (FAB): calcd. for C 15 H 28N 3(M+H-3HClt:
250.22S3; found: 250.226S.
N-(4-Amino-butyl)-N'-naphthalen-1-ylmethyl-butane-1,4diamine Trihydrochloride (27b ). White solid; yield SO%. 1H
NMR (300MHz, D20): oS.03 (brs, lH), 7.96 (brs, 2H), 7.59
(br s, 2H), 7.53 (br s, lH), 7.51 (br s, lH), 4.6S (s, 2H), 3.14
(t, 2H), 2.99 (m, 6H), 1.67 (br s, S). 13 C NMR (D 20): 132.9,
130.2, 129.9, 12S.S, 12S.5, 126.S, 126.0, 125.S, 125.0, 121.9,
47.4, 46.5, 46.4, 46.3, 3S.4, 23.5, 22.5, 22.4 (2C); HRMS
(FAB): calcd. forC 19 H30N 3 (M+H-3HClt: 300.2440; found:
300.2431.
N-(4-Amino-butyl)-N'-pyren-1-ylmethyl-butane-1,4-diamine Trihydrochloride (27d). White solid; yield 94%. NMR
(300 MHz, D 20): o S.1-7.6 (m, 9H), 4.46 (s, 2H), 3.04 (m,
2H), 2.92 (m, 6H), 1.63 (br s, SH). 13 C NMR (D 20): o 131.3,
130.4, 129.7, 12S.4, 12S.2, 127.9, 126.9, 126.3, 125.7, 125.6,
124.53, 124.51, 123.1, 122.9, 122.5, 120.9, 47.9, 47.0, 46.9,
46.6, 39.0, 24.1, 23.0, 22.9 (2C). HRMS (FAB): calcd. for
C 25 H31 N 3(M+H-3HClt; 374.2596; found: 374.2594.
l-Amino-3-{ 4-[ (anthracen-9-ylmethyl)-amino ]-butylamino }-propan-2-ol Trihydrochloride (30) Bright yellow
solid, yield 95%. NMR (DMSO-d 6 +D 20): o S.SO (s, lH),
S.42 (d, 2H), S.20 (d, 2H), 7.6S (t, 2H), 7.60 (t, 2H), 5.22 (s,
2H), 4.20 (m, lH), 3.2S (t, 2H), 3.1-2.SO (m, 6H), 1.7S (brs,
4H). 13 C NMR (D 20): o 130.6, 130.4, 130.0, 129.5, 127.7,
125.5, 122.5, 120.3, 63.S, 50.1, 47.3, 47.2, 42.S, 42.4, 23.0,
22.9. HRMS (FAB): calcd. for C 22 H30N 30 (M+H-3HClt:
352.23S9; found: 352.23Sl.
N-{ 4-[ (Anthracen-9-ylmethyl)-amino]-butyl }-cyclohexane1,4-diamine Trihydrochloride (31 ). Bright yellow solid, yield
95%. 1HNMR(CD 30D): oS.6S (s, lH), S.41(d,2H), S.17 (d,
2H), 7.6S (t, 2H), 7.57 (t, 2H), 5.34 (s, 2H), 3.40 (m, 2H), 3.16
(m, 4H), 2.26 (m, 2H), 2.20 (m, 2H), 1.90 (m, 4H), 1.60 (m,
4H); 13 C NMR (D 20): o 130.7, 130.4, 130.1, 129.5, 127.7,
125.5, 122.5, 120.3, 55.4, 4S.7, 47.1, 44.3, 42.S, 2S.2, 26.S,
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23.3, 23.0. HRMS (FAB): calcd. for C 25 H34N 3 (M+H3HClt; 376.2753; found: 376.2747.
N 1-Anthracen-9-ylmethyl-octane-l ,S-diamine Dihydrochloride (32). yellow solid; yield S9%; 1H NMR (300 MHz,
CD 30D) o S.69 (s, lH), S.40 (d, 2H), S.15 (d, 2H), 7.70 (t,
2H), 7.59 (t, 2H), 5.32 (s, 2H), 3.30 (br s, 2H), 2.92 (t 2H),
1.S2 (m, 2H), 1.63 (m, 2H), 1.42 (br s, SH); 13 C NMR (D 20):
o130.6, 130.3, 130.0, 129.4, 127.6, 125.5, 122.4, 120.5, 47.S,
42.3, 39.7, 2S.2, 2S.1, 26.9, 25.9, 25.7, 25.4; HRMS (FAB)
mlz calcd. for C 23 H31 N 2 (M+H-2HClt; 335.24S7; found:
335.24S9.
2-(2-{ 2-[ (Anthracen-9-ylmethyl)-amino ]-ethoxy }-ethoxy)ethylamine Dihydrochloride (33). Bright yellow solid; yield
S1%; 1H NMR (300 MHz, DMSO-d 6 +D 20) o S.SO (s, lH),
S.40 (d, 2H), S.20 (d, 2H), 7.6S (t, 2H), 7.60 (t, 2H), 5.24 (s,
2H), 3.S2 (t, 2H), 3.66 (m, 4H), 3.60 (t, 2H), 3.40 (t, 2H), 2.96
(t, 2H); 13 C NMR (D 20): o130.S, 130.5, 130.1, 129.5, 127.7,
125.6, 122.5, 120.5, 69.S (2C), 66.6, 65.1, 47.0, 42.5, 39.2.
HRMS (FAB) m/z calcd. for: C 21 H 27N 20 2 (M+H-2HClt:
339.2073; found: 339.2074.
N 1-Anthracen-9-ylmethyl-butane-l ,4-diamine Dihydrochloride (34). Yellow solid; yield 21 %; Rf=0.11, methanol/chloroform, 1:20+3 drops of NH40H); 1H NMR (300 MHz,
D20): o S.55 (br s, lH), S.15 (d, 2H), S.OS (d, 2H), 7.66 (m,
4H), 5.0S (br s, 2H), 3.25 (t, 2H), 3.0 (t, 2H), 1.76 (m, 4H); 13 C
NMR (D 20): o 130.6, 130.3, 129.9, 129.4, 127.6, 125.4,
122.4, 120.2, 47.2, 42.7, 3S.6, 24.2, 22.9; ESI-MS m/z calcd.
for C 19 H 23 N 2 (M+H): 279.2; found: 279.2.
N 1-Anthracen-9-y lmethy1-buty!amine Monohydrochloride
(35) Compound35 was synthesized in 5S% yield by reductive
amination of anthraldehyde and butylamine followed by
treatment with 4N aq. HCI. 35: Yellow solid; yield 5S%;
Rf=0.5, methanol/chloroform, 1:20+1 drop of NH40H; 1H
NMR (300 MHz, DMSO-d 6 ): o9.1 (br s, 2H, NH 2 salt), S.7S
(s, lH), S.51(d,2H), S.lS (d, 2H), 7.64 (m, 4H), 5.2 (brs, 2H),
3.2 (s, 2H), 1.73 (t, 2H), 1.36 (q, 2H), 0.92 (q, 3H); 13 C NMR
(CDC1 3): o 131.6, 131.26, 130.55, 129.46, 12S.05, 125.72,
123.S9, 120.S6, 46.05, 41.92, 2S.4S, 20.32, 13.79. Anal.
Calcd for C 15 H 22 NC1, 0.2H 20: C, 75.21; H, 7.44; N, 4.62;
found: C, 75.31; H, 7.44; N, 4.56.
As is apparent from the above Tables 1-3, a limited class of
N-alkylarylpolyamine compounds (i.e. N-naphthylalkyl,
N-anthracenylalkyl and N-pyrenylalkyl) have unique properties of surprising cytotoxicity, unexpected selectivity in killing cancer cells (especially cells with high polyamine transport activity), and/or facilitate the delivery of known toxic
agents into cancer cells. As shown in Table 2, the N-(3Amino-propyl)-N-anthracen-9-ylmethyl-butane-1,4-diamine, trihydrochloride (Sd), N-(4-Amino-butyl)-N-anthracen-9-ylmethyl-butane-1,4-diamine, trihydrochloride (Se),
N-( 4-Amino-butyl)-N-anthracen-9-ylmethyl-pentane-1,5diamine, trihydrochloride (Sg). N-(4-Amino-butyl)-N'-naphthalen-1-ylmethyl-butane-1,4-diamine
trihydrochloride
(27b ), N-( 4-Amino-butyl)-N-pyren-1-ylmethyl-butane-1,4diamine trihydrochloride (27d), and N-{ 4-[(Anthracen-9-ylmethyl)-amino ]-butyl}-cyclohexane-1,4-diamine trihydrochloride (31) have outstanding selectivity in targeting and
killing cells with active polyamine transporters.
N-Alkylpolyamines can be broken down into their dealkylated components by cellular metabolic pathways. For
example, a N-alkyl-4,4-triamine (RNH(CH 2)4NH(CH 2)4
NH 2, where R is alkyl) can be converted into homospermidine, H 2N(CH 2)4NH(CH 2)4NH 2. It has been found that the
N-alkylaryl group has an influence on this breakdown path-
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way. Surprisingly, cells treated with compound Se did not
form homospermidine, which indicated stability towards this
form of degradation.
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NMDA receptor to excess glutamate, essentially blocking its
detrimental effect. The IC 50 data (i.e., the concentration of the
polyamine or drug required to inhibit the function of the
NMDA or AMPA receptor by 50%) show that the polyamine
conjugate of the present invention (13b) selectively inhibits
Example 4
both the NR1/NR2A and NR1/NR2B receptors. which are
responsible for damage. This desired effect on the two NRl/
NR2A and NR1/NR2B type receptors is accomplished with
only a very small quantity of the polyamine conjugate, 13b,
Biolo ical Data
1o 0 .065 µMand 0 .179 µM, respectively. A much larger quantity,
2.060 µM, of 13b is needed to block the function of the good
IC 50 for NR1/NR2A *
receptor, AMPA to the same level (50% function). Therefore,
Memantinea
0.460 µM
tetraamine 13b has clear selectivity for inhibiting the detriAnthracene-Spermine (13b)
0.065 µM
mental receptors (NR1/NR2A and NR1/NR2B), while main519.0 µM
Spermine
15 taining the action of the good receptor (AMPA).
Anthracene
no effect
FIG.10 shows the effect ofanthracene-spermine, 13b, on
*NR2A predominates the fore brain (cerebral cortex)
NMDA and AMPA receptors. Anthracene-spermine is in the
a drug currently used for Alzheimer's treatment
class of compounds having formula B: RNR 1 (CH 2 )rNR2
µM = micromolar
(CH 2 ) 5 NR3 (CH 2 ),NR4 R 5 wherein R is anthracenylmethyl,
Example 4 shows that anthracene-spermine (13b) blocks 20 R1, R 2 , R 3 , R4 , R 5 ishydrogenandris3, sis 4, andtis3; it is
NMDA receptor cells very efficiently with an IC 50 value of
also known by the abbreviated name, "Ant343".
0.065 µM, whereas a current drug, Memantine, now used in
As shown in FIG. 11, anthracene without a polyamine
Alzheimer's treatments has an IC 50 value of0.460 µM. The
attached is not effective in controlling or inhibiting the activcompound 13b of the present invention is therefore, seven
ity of the NMDAreceptor, NR1A/NR2A. From Oto 50microtimes more potent and can lead to a new therapy for human 25
molar concentration (µM) of anthracene were used and the
diseases which involve the NMDA receptor. Spermine alone
NMDA receptor maintained greater than 80% function. In
(without anthracene) requires much higher doses ( 519 µM) in
other words, no IC 50 value could be determined from FIG.11,
order to elicit the same response as 13b (at 0.065 µM). Moresince even at the highest dose (50 µM), the receptor had
over, anthracene alone (without an attached polyamine) has
greater than 85% function. Therefore, without the appended
no effect at physiological relevant concentrations (<40 µM); 30
polyamine molecular recognition element attached, the
see also FIG. 11. This reveals that one needs a combination of
anthracene ring was not an efficacious inhibitor for the
the two molecules in order to gain the high selectivity
NMDA receptor.
observed in 13b. This is an unexpected result.
Thus, it is demonstrated that the tetraamine derivatives of
35 the present invention are "smart" molecules that can be very
Example 5
selective in inhibiting the function of NMDA receptors that
cause nerve cell death, while allowing other receptors, such as
GluRl, to function normally within nerve cells, subjected to
the trauma of stroke, Alzheimer's disease and the like. The
Selectivity Based upon IC 50 Data
40
lower IC 50 values in Examples 4 and 5 mean that less drug is
needed to block 50% of the function of each receptor. When
NR1/NR2A*
NR1/NR2B*
AMPA
administered in less than a toxic amount, the tetraamine
Ant-3,4,3 (Anthracene0.065 µM
0.179 µM
2.060 µM
derivatives of the present invention provide a selective and
spermine) Conjugate 13b
45 potent new therapy for the treatment of neurodegenerative
*NR1/NR2A and NR1/NR2B are subunits ofNMDA receptors in the adult
disorders, such as, brain stoke and Alzheimer's disease.
central nervous system predominating in the forebrain (cerebral cortex).
While the invention has been described, disclosed, illusAMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropitrated and shown in various terms of certain embodiments or
onic acid) is a known protective receptor and the inhibition of
modifications which it has presumed in practice, the scope of
AMPA would be detrimental to treatment of brain disorders. 50 the invention is not intended to be, nor should it be deemed to
Spermine has various effects on NMDA receptors (stimulabe, limited thereby and such other modifications or embodition or voltage-dependent block) which depends on the subments as may be suggested by the teachings herein are parunit composition of the receptors. NR1/NR2B receptors, but
ticularly reserved especially as they fall within the breadth
not NR1/NR2A receptors, are stimulated by spermine in the
and scope of the claims here appended.
presence of saturating levels of agonists. However, both sub- 55
types (NR1/NR2B and NR1/NR2A receptors) are blocked in
I claim:
a voltage dependent manner by spermine. Therefore, by
1. A method for selectively inhibiting N-Methyl-D-Asparstudying the effects of 13b on these two receptors one can
tate (NMDA) receptors present in the adult central nervous
deconvolute the mechanism of action ofl 3b. Low IC 50 values
system comprising the step of administering N-(3-Aminoin the NR1/NR2A experiment suggests that the conjugate is 60
propy
1)-N-{ 3-[ (anthracen-9-ylmethyl )-amino ]-propy1}-busuccessfully inhibiting the receptor via a voltage-dependent
tane-1,4-diamine tetrahydrochloride, referred to as
block. On the other hand, by looking at the NR1/NR2B recepanthracene-spermine, 13b,
tors, one can assess whether the NMDA receptor is actually
stimulated by 13b in the presence of glutamate (the molecule
to a subject requiring treatment for a neurodegenerative
which can hyperstimulate NMDA and cause neuron cell 65
disorder, thereby selectively inhibiting detrimental
death). A low IC 50 value with the NR1/NR2B receptors sugreceptors, NR1/NR2A and NR1/NR2B, while maintaingests that 13b is actually inhibiting the response of the
ing the action of the good receptor, AMPA.
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2. The method of claim 1 wherein the neurodegenerative
disorder is selected from the group consisting of stroke,
Alzheimer's disease and Parkinson's disease.
3. A method for selectively inhibiting N-Methyl-D-Aspartate (NMDA) receptors present in the adult central nervous
system comprising the step of administering an effective
amount of N-(3-Amino-propyl)-N-{3-[(anthracen-9-ylmethyl)-amino]-propyl }-butane-1,4-diamine tetrahydrochloride, referred to as anthracene-spermine, 13b, to a subject

requiring treatment for a neurodegenerative disorder, thereby
selectively inhibiting specific NMDA receptors, NR1/NR2A
subunit and NR1/NR2B subunit, while maintaining the action
of the receptor, AMPA.
4. The method of claim 3 wherein the neurodegenerative
disorder is selected from the group consisting of stroke,
Alzheimer's disease and Parkinson's disease.
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